Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04587323 · ClinicalTrials.gov registry record
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 75
- Enrollment target
NCT04587323: Completed study, sponsored by University of Alabama at Birmingham.
NCT04587323 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04587323 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death.
Primary Outcome
The primary outcome measure is the ratio of soluble fms-like tyrosine kinase receptor-1 (sFlt-1) to vascular endothelial growth factor (VEGF) which will be obtained using an immunoassay on blood samples. The specimens will be analyzed using enzyme-linked immunosorbent assay and reported as a ratio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2025-10-06 |
What the finished NCT04587323 record still lists
NCT04587323 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04587323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04587323 about?
NCT04587323 is a clinical study titled "VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease". To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respir...
What is the current status of trial NCT04587323?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2020-05-22. Estimated completion is 2025-10-06.
Who is sponsoring clinical trial NCT04587323?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI